Zacks: Sonoma Pharmaceuticals, Inc. (SNOA) Given $11.00 Consensus Price Target by Analysts

Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus price target of $11.00 for the company and are anticipating that the company will post ($0.63) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Sonoma Pharmaceuticals an industry rank of 111 out of 265 based on the ratings given to its competitors.

A number of research analysts have issued reports on the stock. ValuEngine lowered shares of Sonoma Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Maxim Group set a $11.00 target price on shares of Sonoma Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 17th.

An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. Renaissance Technologies LLC lifted its position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 227.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,622 shares of the company’s stock after acquiring an additional 31,000 shares during the period. Renaissance Technologies LLC owned approximately 1.05% of Sonoma Pharmaceuticals worth $320,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 9.22% of the company’s stock.

Shares of Sonoma Pharmaceuticals (NASDAQ SNOA) traded down $0.07 during trading hours on Friday, hitting $5.01. 8,600 shares of the company’s stock were exchanged, compared to its average volume of 31,006. Sonoma Pharmaceuticals has a 1 year low of $4.16 and a 1 year high of $8.25. The firm has a market cap of $22.06, a price-to-earnings ratio of -2.52 and a beta of 1.20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.56 and a current ratio of 5.37.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://weekherald.com/2017/12/25/zacks-sonoma-pharmaceuticals-inc-snoa-given-11-00-consensus-price-target-by-analysts.html.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Get a free copy of the Zacks research report on Sonoma Pharmaceuticals (SNOA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply